Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors

Initial sequencing and analysis of the human genome

International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216 · see citing works

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · see citing works

Molecular and genetic properties of tumors associated with local immune cytolytic activity

Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · see citing works

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548 · see citing works

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · see citing works

Tumor mutational burden and response rate to PD-1 inhibition

Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · see citing works

Molecular mechanisms of T cell co-stimulation and co-inhibition

Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114 · see citing works

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · see citing works

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065 · see citing works

Cancer immunotherapy: moving beyond current vaccines

Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,956 · see citing works

An immunogenic personal neoantigen vaccine for patients with melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · see citing works

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · see citing works

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,492 · see citing works

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · see citing works

NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data

Reynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa379 · Cited by 2,361 · see citing works

Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability

Markowitz, S. D., Wang, J., Myeroff, L. L., Parsons, R. E., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,267 · see citing works

Cancer immunoediting and resistance to T cell-based immunotherapy

O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759 · see citing works

Human papillomavirus oncoproteins: pathways to transformation

Moody, C. A., & Laimins, L. A. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2886 · Cited by 1,757 · see citing works

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,710 · see citing works

Oncolytic viruses: a new class of immunotherapy drugs

Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,651 · see citing works

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C.-H., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,635 · see citing works

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527 · see citing works

NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data

Jurtz, V. I., Paul, S., Andreatta, M., Marcatili, P., Peters, B., & Nielsen, M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700893 · Cited by 1,476 · see citing works

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432 · see citing works

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421 · see citing works

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368 · see citing works

IL-2: The First Effective Immunotherapy for Human Cancer

Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,297 · see citing works

A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285 · see citing works

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260 · see citing works

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Morgan, R. A., Chinnasamy, N., Abate‐Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,155 · see citing works

A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma

Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann, E., Plaen, E. D., Hankeln, T., Büschenfelde, K. M. Z., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,153 · see citing works

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

Robbins, P. F., Lu, Y., El‐Gamil, M., Li, Y. F., Gross, C. A., Gartner, J. J., Lin, J., Teer, J. K., Cliften, P. F., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,074 · see citing works

Towards personalized, tumour-specific, therapeutic vaccines for cancer

Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067 · see citing works

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

Parkhurst, M. R., Yang, J. C.-H., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,025 · see citing works

PyClone: statistical inference of clonal population structure in cancer

Roth, A. J. L., Khattra, J. S., Yap, D., Wan, A. N. C., Laks, E., Biele, J., Ha, G., Aparicio, S. A. J. R., Bouchard‐Côté, A., & Shah, S. P. (2014) · Nature Methods · doi:10.1038/nmeth.2883 · Cited by 1,002 · see citing works

Actively personalized vaccination trial for newly diagnosed glioblastoma

Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938 · see citing works

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6458 · Cited by 914 · see citing works

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin‐Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.075 · Cited by 912 · see citing works

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Bakir, M. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 909 · see citing works

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

Kahles, A., Lehmann, K.-V., Toussaint, N. C., Hüser, M., Stark, S. G., Sachsenberg, T. T., Stegle, O., Kohlbacher, O., Sander, C., Johnson, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.001 · Cited by 891 · see citing works

Targeting mutant p53 for efficient cancer therapy

Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889 · cited 1× · see citing works

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., & Rosenberg, S. A. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.1.347 · Cited by 861 · see citing works

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798 · see citing works

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

Zacharakis, N., Chinnasamy, H., Black, M. A., Xu, H., Lu, Y., Zheng, Z., Pasetto, A., Langhan, M. M., Shelton, T. E., Prickett, T. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0040-8 · Cited by 774 · see citing works

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Lamers, C. H., Sleijfer, S., van Steenbergen, S. C. L., van Elzakker, P., Krimpen, B. A. V., Groot, C., Vulto, A. G., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 706 · see citing works

Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry

Bassani-Sternberg, M., Bräunlein, E., Klar, R., Engleitner, T., Sinitcyn, P., Audehm, S., Straub, M., Weber, J., Slotta-Huspenina, J., Specht, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13404 · Cited by 693 · see citing works

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

Cameron, B., Gerry, A. B., Dukes, J. D., Harper, J. V., Kannan, V., Bianchi, F., Grand, F., Brewer, J. E., Gupta, M., Plesa, G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006034 · Cited by 685 · see citing works

The emerging complexity of gene fusions in cancer

Mertens, F., Johansson, B., Fioretos, T., & Mitelman, F. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3947 · Cited by 675 · see citing works

Clinical lessons learned from the first leg of the CAR T cell journey

Majzner, R. G., & Mackall, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0564-6 · Cited by 636 · see citing works

DNA Methylation Is the Primary Silencing Mechanism for a Set of Germ Line- and Tumor-Specific Genes with a CpG-Rich Promoter

Smet, C. D., Lurquin, C., Lethé, B., Martelange, V., & Boon, T. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7327 · Cited by 598 · see citing works

Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

Gao, Q.-S., Liang, W.-W., Foltz, S., Mutharasu, G., Jayasinghe, R., Cao, S., Liao, W.-W., Reynolds, S., Wyczalkowski, M., Yao, L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.050 · Cited by 557 · see citing works

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., & Rosenberg, S. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1185 · Cited by 550 · see citing works

Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response

Mandal, R., Samstein, R. M., Lee, K.-W., Havel, J. J., Wang, H., Krishna, C., Sabio, E. Y., Makarov, V., Kuo, F., Blecua, P., et al. (2019) · Science · doi:10.1126/science.aau0447 · Cited by 549 · see citing works

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

Fisk, B. A., Blevins, T. L., Wharton, J. T., & Ioannides, C. G. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.6.2109 · Cited by 544 · see citing works

Role of non-coding sequence variants in cancer

Khurana, E., Fu, Y., Chakravarty, D., Demichelis, F., Rubin, M. A., & Gerstein, M. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.17 · Cited by 448 · see citing works

'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations

Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443 · see citing works

CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens

de Almeida, L. G. P., Sakabe, N. J., deOliveira, A. R., da Silva, M. C. C., Mundstein, A. S., Cohen, T., Chen, Y., Chua, R., Gurung, S., Gnjatic, S., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn673 · Cited by 436 · see citing works

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma

D’Angelo, S. P., Melchiori, L., Merchant, M. S., Bernstein, D. B., Glod, J. W., Kaplan, R. N., Grupp, S. A., Tap, W. D., Chagin, K., Binder, G. K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1417 · Cited by 432 · see citing works

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

Coulie, P. G., Lehmann, F. F., Lethé, B., Herman, J., Lurquin, C., Andrawiss, M., & Boon, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7976 · Cited by 423 · see citing works

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Goff, S. L., Dudley, M. E., Citrin, D. E., Somerville, R. P. T., Wunderlich, J. R., Danforth, D. N., Zlott, D. A., Yang, J. C., Sherry, R. M., Kammula, U. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7220 · Cited by 410 · see citing works

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.

Skipper, J., Hendrickson, R. C., Gulden, P. H., et al. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.2.527 · Cited by 409 · see citing works

Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions

Lu, Y., Yao, X., Crystal, J. S., Li, Y. F., El‐Gamil, M., Gross, C. A., Davis, L., Dudley, M. E., Yang, J. C.-H., Samuels, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0433 · Cited by 401 · see citing works

Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers.

Grady, W. M., Myeroff, L. L., Swinler, S. E., Rajput, A., Thiagalingam, S., Lutterbaugh, J., Neumann, A., Brattain, M. G., Chang, J., Kim, S., et al. (1999) · PubMed · Cited by 391 · see citing works

Translation from the 5′ untranslated region shapes the integrated stress response

Starck, S. R., Tsai, J. C., Chen, K., Shodiya, M., Wang, L., Yahiro, K., Martins‐Green, M. M., Shastri, N., & Walter, P. (2016) · Science · doi:10.1126/science.aad3867 · Cited by 390 · see citing works

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Rugo, H. S., Delord, J., Im, S., Ott, P. A., Piha-Paul, S. A., Bedard, P. L., Sachdev, J. C., Tourneau, C. L., van Brummelen, E. M. J., Varga, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3452 · Cited by 378 · see citing works

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

Cohen, C. J., Gartner, J. J., Horovitz‐Fried, M., Shamalov, K., Trebska-McGowan, K., Bliskovsky, V. V., Parkhurst, M. R., Ankri, C., Prickett, T. D., Crystal, J. S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82416 · Cited by 374 · see citing works

Immunogenic neoantigens derived from gene fusions stimulate T cell responses

Yang, W., Lee, K.-W., Srivastava, R. M., Kuo, F., Krishna, C., Chowell, D., Makarov, V., Hoen, D. R., Dalin, M. G., Wexler, L. H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0434-2 · Cited by 374 · see citing works

A large fraction of HLA class I ligands are proteasome-generated spliced peptides

Liepe, J., Marino, F., Sidney, J., Jekő, A., Bunting, D. E., Sette, A., Kloetzel, P. M., Stumpf, M. P. H., Heck, A. J. R., & Mishto, M. (2016) · Science · doi:10.1126/science.aaf4384 · Cited by 368 · see citing works

Landscape of immunogenic tumor antigens in successful immunotherapy of virally-induced epithelial cancer

Stevanović, S., Pasetto, A., Helman, S. R., Gartner, J. J., Prickett, T. D., Howie, B., Robins, H., Robbins, P., Klebanoff, C., Rosenberg, S., et al. (2017) · Science · doi:10.1126/science.aak9510 · Cited by 364 · see citing works

Immune recognition of a human renal cancer antigen through post-translational protein splicing

Hanada, K., Yewdell, J. W., & Yang, J. C.-H. (2004) · Nature · doi:10.1038/nature02240 · Cited by 337 · see citing works

The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy

Lindeboom, R. G. H., Vermeulen, M., Lehner, B., & Supek, F. (2019) · Nature Genetics · doi:10.1038/s41588-019-0517-5 · Cited by 327 · see citing works

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance

Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 325 · see citing works

Intron retention is a source of neoepitopes in cancer

Smart, A., Margolis, C. A., Pimentel, H., He, M. X., Miao, D., Adeegbe, D. O., Fugmann, T., Wong, K., & Allen, E. M. V. (2018) · Nature Biotechnology · doi:10.1038/nbt.4239 · Cited by 321 · see citing works

Unconventional T Cell Targets for Cancer Immunotherapy

Godfrey, D. I., Nours, J. L., Andrews, D. M., Uldrich, A. P., & Rossjohn, J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.009 · Cited by 318 · see citing works

Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma

Smith, C. C., Beckermann, K. E., Bortone, D. S., De Cubas, A. A., Bixby, L. M., Lee, S. J., Panda, A., Ganesan, S., Bhanot, G., Wallen, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121476 · Cited by 303 · see citing works

Genome-wide ribosome profiling reveals complex translational regulation in response to oxidative stress

Gerashchenko, M. V., Lobanov, A. V., & Gladyshev, V. N. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120799109 · Cited by 302 · see citing works

Structure of the gene of tum− transplantation antigen P91A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cells

Lurquin, C., Pel, A. V., Mariamé, B., et al. (1989) · Cell · doi:10.1016/0092-8674(89)90844-1 · Cited by 301 · see citing works

Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay

Pastor, F., Kolonias, D. S., Giangrande, P. H., & Gilboa, E. (2010) · Nature · doi:10.1038/nature08999 · Cited by 297 · see citing works

Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers

Parkhurst, M. R., Robbins, P. F., Tran, E., Prickett, T. D., Gartner, J. J., Jia, L., Ivey, G. D., Li, Y. F., El‐Gamil, M., Lalani, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1494 · Cited by 290 · see citing works

Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA

Paulson, K. G., Voillet, V., McAfee, M. S., Hunter, D. S., Wagener, F. D., Perdicchio, M., Valente, W. J., Koelle, S., Church, C. D., Vandeven, N. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06300-3 · Cited by 286 · see citing works

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3

Lu, Y., Parker, L. L., Lu, T., Zheng, Z., Toomey, M. A., White, D. E., Yao, X., Li, Y. F., Robbins, P. F., Feldman, S. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5463 · Cited by 278 · see citing works

Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers

Malekzadeh, P., Pasetto, A., Robbins, P. F., Parkhurst, M. R., Paria, B. C., Jia, L., Gartner, J. J., Hill, V. K., Yu, Z., Restifo, N. P., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123791 · Cited by 277 · see citing works

T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study

Doran, S. L., Stevanović, S., Adhikary, S., Gartner, J. J., Jia, L., Kwong, M. L. M., Faquin, W. C., Hewitt, S. M., Sherry, R. M., Yang, J. C.-H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02424 · Cited by 275 · see citing works

Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer

Sæterdal, I., Bjørheim, J., Lislerud, K., Klemp, M., Bukholm, I. K., Olsen, O. C., Nesland, J. M., Eriksen, J. A., Møller, M., Lindblom, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231326898 · Cited by 273 · see citing works

Therapeutic cancer vaccines: Are we there yet?

Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271 · see citing works

Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames

Laumont, C. M., Daouda, T., Laverdure, J., Bonneil, É., Caron-Lizotte, O., Hardy, M., Granados, D. P., Durette, C., Lemieux, S., Thibault, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms10238 · Cited by 269 · see citing works

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin‐Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.009 · Cited by 259 · see citing works

Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.

Wang, R. F., Parkhurst, M. R., Kawakami, Y., Robbins, P. F., & Rosenberg, S. A. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.3.1131 · Cited by 255 · see citing works

Different affinity windows for virus and cancer‐specific T ‐cell receptors: Implications for therapeutic strategies

Aleksic, M., Liddy, N., Molloy, P. E., Pumphrey, N. J., Vuidepot, A., Chang, K., & Jakobsen, B. K. (2012) · European Journal of Immunology · doi:10.1002/eji.201242606 · Cited by 250 · see citing works

Systematic Analysis of Splice-Site-Creating Mutations in Cancer

Jayasinghe, R. G., Cao, S., Gao, Q., Wendl, M. C., Vo, N. S., Reynolds, S. M., Zhao, Y., Climente-González, H., Chai, S., Wang, F., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.052 · Cited by 241 · see citing works

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.

Yotnda, P., Firat, H., Garcia‐Pons, F., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci488 · Cited by 240 · see citing works

Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors

Wang, Q. J., Yu, Z., Griffith, K., Hanada, K.-I., Restifo, N. P., & Yang, J. C. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0188 · Cited by 240 · see citing works

Frameshift peptide-derived T-cell epitopes: A source of novel tumor-specific antigens

Linnebacher, M., Gebert, J. F., Rudy, W., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1298 · Cited by 234 · see citing works

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.

Guilloux, Y., Lucas, S., Brichard, V. G., et al. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.3.1173 · Cited by 231 · see citing works

Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer Therapy

Zhou, J., Dudley, M. E., Rosenberg, S. A., & Robbins, P. F. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200501000-00007 · Cited by 225 · see citing works

A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes

Shichijo, S., Nakao, M., Imai, Y., Takasu, H., Kawamoto, M., Niiya, F., Yang, D., Toh, Y., Yamana, H., & Itoh, K. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.3.277 · Cited by 214 · see citing works

Human Endogenous Retrovirus K Triggers an Antigen-Specific Immune Response in Breast Cancer Patients

Wang‐Johanning, F., Radvanyi, L. G., Rycaj, K., Plummer, J. B., Yan, P., Sastry, K. J., Piyathilake, C. J., Hunt, K. K., & Johanning, G. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6838 · Cited by 212 · see citing works

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Dréno, B., Thompson, J. F., Smithers, B. M., Santinami, M., Jouary, T., Gutzmer, R., Levchenko, E., Rutkowski, P. L., Grob, J., Korovin, S. I., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30254-7 · Cited by 205 · see citing works

A Breast and Melanoma-Shared Tumor Antigen: T Cell Responses to Antigenic Peptides Translated from Different Open Reading Frames

Wang, R., Johnston, S. L., Zeng, G., Topalian, S. L., Schwartzentruber, D. J., & Rosenberg, S. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3596 · Cited by 202 · see citing works

An Antigen Produced by Splicing of Noncontiguous Peptides in the Reverse Order

Warren, E. H., Vigneron, N., Gavin, M. A., Coulie, P. G., Stroobant, V., Dalet, A., Tykodi, S. S., Xuereb, S. M., Mito, J. K., Riddell, S. R., et al. (2006) · Science · doi:10.1126/science.1130660 · Cited by 201 · see citing works

Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals

Maeda, Y., Nishikawa, H., Sugiyama, D., Ha, D., Hamaguchi, M., Saito, T., Nishioka, M., Wing, J. B., Adeegbe, D. O., Katayama, I., et al. (2014) · Science · doi:10.1126/science.aaa1292 · Cited by 200 · see citing works

Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy

Zarling, A. L., Polefrone, J. M., Evans, A. M., Mikesh, L. M., Shabanowitz, J., Lewis, S. T., Engelhard, V. H., & Hunt, D. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604045103 · Cited by 193 · see citing works

Untitled work

(2002) · PubMed · Cited by 193 · see citing works

Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells

Takahashi, Y., Harashima, N., Kajigaya, S., Yokoyama, H., Cherkasova, E. A., McCoy, J. P., Hanada, K., Mena, O. J., Kurlander, R. J., Tawab, A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34409 · Cited by 190 · see citing works

Expanding the computational toolbox for mining cancer genomes

Ding, L., Wendl, M. C., McMichael, J. F., & Raphael, B. J. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3767 · Cited by 184 · see citing works

Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6

Draper, L. M., Kwong, M. L. M., Gros, A., Stevanović, S., Tran, E., Kerkar, S. P., Raffeld, M. A., Rosenberg, S. A., & Hinrichs, C. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3341 · Cited by 184 · see citing works

Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma

Panda, A., de Cubas, A. A., Stein, M., Riedlinger, G., Kra, J., Mayer, T., Smith, C. C., Vincent, B. G., Serody, J. S., Beckermann, K. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121522 · Cited by 181 · see citing works

Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells

Takahashi, Y., Harashima, N., Kajigaya, S., Yokoyama, H., Cherkasova, E. A., McCoy, J. P., Hanada, K., Mena, O. J., Kurlander, R. J., Tawab, A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34409c1 · Cited by 180 · see citing works

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade

Shukla, S. A., Bachireddy, P., Schilling, B., Galonska, C., Zhan, Q., Bango, C., Langer, R., Lee, P. C., Gusenleitner, D., Keskin, D. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.026 · Cited by 174 · see citing works

CAR T-cell therapy in hematologic malignancies: a voyage in progress.

Holstein, S. A., & Lunning, M. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1674 · Cited by 172 · see citing works

Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model

Jin, B. E., Campbell, T. E., Draper, L. M., Stevanović, S., Weißbrich, B., Yu, Z., Restifo, N. P., Rosenberg, S. A., Trimble, C. L., & Hinrichs, C. S. (2018) · JCI Insight · doi:10.1172/jci.insight.99488 · Cited by 171 · see citing works

A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands

Faridi, P., Li, C., Ramarathinam, S. H., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aar3947 · Cited by 169 · see citing works

A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas

Mackall, C. L., Rhee, E. H., Read, E. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4065 · Cited by 158 · see citing works

Merkel Cell Polyomavirus-Specific CD8+ and CD4+ T-cell Responses Identified in Merkel Cell Carcinomas and Blood

Iyer, J. G., Afanasiev, O. K., McClurkan, C. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1513 · Cited by 155 · see citing works

T-cell Responses to TP53 “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers

Deniger, D. C., Pasetto, A., Robbins, P. F., Gartner, J. J., Prickett, T. D., Paria, B. C., Malekzadeh, P., Jia, L., Yossef, R., Langhan, M. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0573 · Cited by 154 · see citing works

Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression

Lu, Y., Yao, X., Li, Y. F., El‐Gamil, M., Dudley, M. E., Yang, J. C.-H., Almeida, J. R., Douek, D. C., Samuels, Y., Rosenberg, S. A., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202830 · Cited by 153 · see citing works

Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide.

Sibille, C., Chomez, P., Wildmann, C., et al. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.1.35 · Cited by 151 · see citing works

Determinants for Neoantigen Identification

García-Garijo, A., Fajardo, C. A., & Gros, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01392 · Cited by 136 · see citing works

An antigenic peptide produced by reverse splicing and double asparagine deamidation

Dalet, A., Robbins, P. F., Stroobant, V., Vigneron, N., Li, Y. F., El‐Gamil, M., Hanada, K., Yang, J. C.-H., Rosenberg, S. A., & den Eynde, B. J. V. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101892108 · Cited by 128 · see citing works

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens

Prickett, T. D., Crystal, J. S., Cohen, C. J., Pasetto, A., Parkhurst, M. R., Gartner, J. J., Yao, X., Wang, R., Gros, A., Li, Y. F., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0215 · Cited by 126 · see citing works

The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes

Robbins, P. F., El‐Gamil, M., Li, Y. F., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.1.303 · Cited by 123 · see citing works

Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells

Parkhurst, M. R., Joo, J. S., Riley, J. P., Yu, Z., Li, Y., Robbins, P. F., & Rosenberg, S. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1638 · Cited by 122 · see citing works

T-Cell Therapy Using Interleukin-21–Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression

Chapuis, A. G., Roberts, I. M., Thompson, J. A., Margolin, K. A., Bhatia, S., Lee, S. M., Sloan, H. L., Lai, I. P., Farrar, E. A., Wagener, F. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5142 · Cited by 122 · see citing works

Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens

Malekzadeh, P., Yossef, R., Cafri, G., Paria, B. C., Lowery, F. J., Jafferji, M. S., Good, M. L., Sachs, A., Copeland, A. R., Kim, S. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1874 · Cited by 118 · see citing works

CTL Control of EBV in Nasopharyngeal Carcinoma (NPC): EBV-Specific CTL Responses in the Blood and Tumors of NPC Patients and the Antigen-Processing Function of the Tumor Cells

Lee, S. P., Chan, A. T. �., Cheung, S., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.1.573 · Cited by 117 · see citing works

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy

Depontieu, F., Qian, J., Zarling, A. L., McMiller, T. L., Salay, T. M., Norris, A., English, A. M., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903852106 · Cited by 115 · see citing works

T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product

Huang, J., El‐Gamil, M., Dudley, M. E., Li, Y. F., Rosenberg, S. A., & Robbins, P. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6057 · Cited by 115 · see citing works

Cytotoxicity of Human Endogenous Retrovirus K–Specific T Cells toward Autologous Ovarian Cancer Cells

Rycaj, K., Plummer, J. B., Yin, B., Li, M., Garza, J. G., Radvanyi, L. G., Ramondetta, L. M., Lin, K., Johanning, G. L., Tang, D. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0388 · Cited by 106 · see citing works

Class II major histocompatibility complex tetramer staining: progress, problems, and prospects

Vollers, S. S., & Stern, L. J. (2008) · Immunology · doi:10.1111/j.1365-2567.2007.02801.x · Cited by 106 · see citing works

A Non-AUG-Defined Alternative Open Reading Frame of the Intestinal Carboxyl Esterase mRNA Generates an Epitope Recognized by Renal Cell Carcinoma-Reactive Tumor-Infiltrating Lymphocytes In Situ

Ronsin, C., Chung-Scott, V., Poullion, I., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.483 · Cited by 104 · see citing works

A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

Nowicki, T. S., Berent-Maoz, B., Cheung-Lau, G. C., Huang, R., Wang, X., Tsoi, J., Kaplan‐Lefko, P. J., Cabrera, P. V., Tran, J., Pang, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3496 · Cited by 104 · see citing works

An Alternative Open Reading Frame of the Human Macrophage Colony-Stimulating Factor Gene Is Independently Translated and Codes for an Antigenic Peptide of 14 Amino Acids Recognized by Tumor-Infiltrating Cd8 T Lymphocytes

Probst‐Kepper, M., Stroobant, V., Kridel, R., Gaugler, B., Landry, C., Brasseur, F., Cosyns, J., Weynand, B., Boon, T., & den Eynde, B. J. V. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.10.1189 · Cited by 102 · see citing works

Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1 to human chromosome Xq28

Chen, Y.-T., Boyer, A. D., Viars, C. S., et al. (2008) · Cytogenetics and Cell Genetics · doi:10.1159/000134734 · Cited by 100 · see citing works

Ribosomal scanning past the primary initiation codon as a mechanism for expression of CTL epitopes encoded in alternative reading frames.

Bullock, T. N. J., & Eisenlohr, L. C. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.4.1319 · Cited by 99 · see citing works

SYT ‐ SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the J apanese M usculoskeletal O ncology G roup

Kawaguchi, S., Tsukahara, T., Ida, K., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02370.x · Cited by 96 · see citing works

Detection and Induction of CTLs Specific for SYT-SSX-Derived Peptides in HLA-A24+ Patients with Synovial Sarcoma

Sato, Y., Nabeta, Y., Tsukahara, T., Hirohashi, Y., Syunsui, R., Maeda, A., Sahara, H., Ikeda, H., Torigoe, T., Ichimiya, S., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.3.1611 · Cited by 86 · see citing works

Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood

Peng, S., Zaretsky, J. M., Ng, A. H. C., Chour, W., Bethune, M. T., Choi, J., Hsu, A. C., Holman, E. A., Ding, X., Guo, K. L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.106 · Cited by 83 · see citing works

A TGFβRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8 + T cells

Sæterdal, I., Gjertsen, M., Straten, P. T., et al. (2001) · Cancer Immunology Immunotherapy · doi:10.1007/s002620100222 · Cited by 79 · see citing works

Deciphering the Roles of Innate Lymphoid Cells in Cancer

Bruchard, M., & Ghiringhelli, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00656 · Cited by 79 · see citing works

Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy

Laumont, C. M., & Perreault, C. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2628-4 · Cited by 77 · see citing works

MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases

Kerkar, S. P., Wang, Z.-F., Lasota, J. P., et al. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000119 · Cited by 74 · see citing works

A Spliced Antigenic Peptide Comprising a Single Spliced Amino Acid Is Produced in the Proteasome by Reverse Splicing of a Longer Peptide Fragment followed by Trimming

Michaux, A., Larrieu, P., Stroobant, V., Fonteneau, J., Jotereau, F., den Eynde, B. J. V., Moreau‐Aubry, A., & Vigneron, N. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302032 · Cited by 72 · see citing works

The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis

Wei, Z., Zhou, C., Zhang, Z., Guan, M., Zhang, C., Liu, Z., & Liu, Q. (2019) · iScience · doi:10.1016/j.isci.2019.10.028 · Cited by 67 · see citing works

Identification of BING-4 Cancer Antigen Translated From an Alternative Open Reading Frame of a Gene in the Extended MHC Class II Region Using Lymphocytes From a Patient With a Durable Complete Regression Following Immunotherapy

Rosenberg, S. A., Tong-On, P., Li, Y., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2402 · Cited by 63 · see citing works

Mapping the MHC Class I–Spliced Immunopeptidome of Cancer Cells

Liepe, J., Sidney, J., Lorenz, F. K. M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0424 · Cited by 63 · see citing works

Identification of Natural MHC Class II Presented Phosphopeptides and Tumor-Derived MHC Class I Phospholigands

Meyer, V. S., Drews, O., Günder, M., Hennenlotter, J., Rammensee, H., & Stevanović, S. (2009) · Journal of Proteome Research · doi:10.1021/pr800937k · Cited by 56 · see citing works

Cryptic MHC class I-binding peptides are revealed by aminoglycoside-induced stop codon read-through into the 3′ UTR

Goodenough, E., Robinson, T. M., Zook, M. B., Flanigan, K. M., Atkins, J. F., Howard, M. T., & Eisenlohr, L. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402670111 · Cited by 55 · see citing works

+1 Frameshifting as a Novel Mechanism to Generate a Cryptic Cytotoxic T Lymphocyte Epitope Derived from Human Interleukin 10

Saulquin, X., Scotet, E., Trautmann, L., Peyrat, M., Halary, F. A., Bonneville, M., & Houssaint, E. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011399 · Cited by 51 · see citing works

Initiation Codon Scanthrough versus Termination Codon Readthrough Demonstrates Strong Potential for Major Histocompatibility Complex Class I–restricted Cryptic Epitope Expression

Bullock, T. N. J., Patterson, A. E., Franlin, L. L., Notidis, E., & Eisenlohr, L. C. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1051 · Cited by 49 · see citing works

Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer

Chae, Y. K., de Viveiros, P. A. H., Junior, G. L. L., Sukhadia, B., Sheikh, M. M., Saravia, D., Florou, V., Sokol, E. S., Frampton, G. M., Chalmers, Z. R., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.016 · Cited by 49 · see citing works

Nasopharyngeal Carcinoma

Lung, M. L., Dai, W., & Ko, J. M. Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814936-2.00002-x · Cited by 46 · see citing works

Not-So-Negative Selection

Davis, M. M. (2015) · Immunity · doi:10.1016/j.immuni.2015.11.002 · Cited by 42 · see citing works

Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers

Rössig, C., Kailayangiri, S., Jamitzky, S., & Altvater, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00513 · Cited by 42 · see citing works

Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations

Hansen, U. K., Ramskov, S., Bjerregaard, A.-M., Borch, A., Andersen, R. S., Draghi, A., Donia, M., Bentzen, A. K., Marquard, A. M., Szállási, Z., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00373 · Cited by 42 · see citing works

Androgenic regulation of growth factor and growth factor receptor expression in the cwr22 model of prostatic adenocarcinoma

Myers, R. B., Oelschlager, D. K., Manne, U., Coan, P. N., Weiss, H. L., & Grizzle, W. E. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990730)82:3 · Cited by 37 · see citing works

Melanoma-Reactive CD8 + T Cells Recognize a Novel Tumor Antigen Expressed in a Wide Variety of Tumor Types

Harada, M., Li, Y. F., El‐Gamil, M., et al. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200107000-00008 · Cited by 34 · see citing works

The Melanoma Antigens MELOE-1 and MELOE-2 Are Translated from a Bona Fide Polycistronic mRNA Containing Functional IRES Sequences

Carbonnelle, D., Vignard, V., Séhédic, D., Moreau‐Aubry, A., Florenceau, L., Charpentier, M., Mikulits, W., Labarrière, N., & Lang, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075233 · Cited by 34 · see citing works

Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer

Kalina, J. L., Neilson, D. S., Lin, Y., Hamilton, P. T., Comber, A. P., Loy, E. M. H., Şahinalp, S. C., Collins, C. C., Hach, F., & Lum, J. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0618 · Cited by 25 · see citing works

Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).

Voss, M. H., Buros, J. L., Hellmann, M. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4518 · Cited by 22 · see citing works

Is allogeneic transplant for solid tumors still alive?

Bregni, M., Badoglio, M., Pedrazzoli, P., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.345 · Cited by 13 · see citing works

Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).

Pignon, J., Jegede, O. A., Shukla, S. A., Braun, D. A., Horak, C. E., Wind‐Rotolo, M., Ishii, Y., Catalano, P. J., Freeman, G. J., Jennings, R. B., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4568 · Cited by 10 · see citing works

Regression of Epithelial Cancers Following T Cell Receptor Gene Therapy Targeting Human Papillomavirus-16 E7

Norberg, S. M., Nagarsheth, N., Doran, S. L., et al. (2018) · Blood · doi:10.1182/blood-2018-99-117017 · Cited by 9 · see citing works

A neoepitope derived from a novel human germline APC gene mutation in familial adenomatous polyposis shows selective immunogenicity

Majumder, S., Shah, R., Elias, J., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203845 · Cited by 6 · see citing works

Cancer Immunotherapy for Nasopharyngeal Carcinoma

Kwong, D. L. W., Lee, V., & Nicholls, J. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814936-2.00015-8 · Cited by 2 · see citing works

Therapeutic cancer vaccines: Advancements, challenges, and prospects

Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597 · see citing works

Lighting up the fire in the microenvironment of cold tumors: a major challenge to improve cancer immunotherapy

Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39 · see citing works

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works

Advances in adoptive cellular therapy for colorectal cancer: A narrative review

Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14 · see citing works

Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators

Debele, T. A., Yeh, C.-F., & Su, W. (2020) · Cancers · doi:10.3390/cancers12123773 · Cited by 87 · see citing works

pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review

Yan, Y., & Ding, H. (2020) · Nanomaterials · doi:10.3390/nano10081613 · Cited by 108 · see citing works

Nanotechnology-Based Bacterial Immunotherapy

Arya, R. K. K., Sati, D., Bisht, D., et al. (2022) · Springer eBooks · doi:10.1007/978-981-19-2507-8_1 · Cited by 1 · see citing works

Triggering Immune System With Nanomaterials for Cancer Immunotherapy

Liu, Y., Liu, Y., Huang, Z., Guo, Y., & Li, Q. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.878524 · Cited by 24 · see citing works

Cancer Physical Hallmarks as New Targets for Improved Immunotherapy

Guo, H., Zhang, T., Yu, Y., et al. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.03.011 · Cited by 27 · see citing works